We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

66 hedge funds and large institutions have $95.4M invested in LENZ Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

17% more call options, than puts

Call options by funds: $446K | Put options by funds: $382K

5% more funds holding

Funds holding: 63 → 66 (+3)

5% more capital invested

Capital invested by funds: $91.2M → $95.4M (+$4.24M)

0.19% less ownership

Funds ownership: 7.27% → 7.08% (-0.19%)

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
1.06%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
13
Increased
21
Reduced
15
Closed
9
Calls
$446K
Puts
$382K
Net Calls
+$64K
Net Calls Change
-$37K

Top Buyers

1
EC
EcoR1 Capital
California
+$13.7M
2
PM
Prosight Management
Texas
+$1.85M
3
AFM
Anson Funds Management
Texas
+$371K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$273K
5
Man Group
Man Group
United Kingdom
+$240K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.4M
2
OM
Opaleye Management
Massachusetts
-$1.83M
3
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$807K
4
Goldman Sachs
Goldman Sachs
New York
-$739K
5
Millennium Management
Millennium Management
New York
-$720K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$28.1M – – –
EC
2
EcoR1 Capital
California
$19M +$13.7M +589,995 +261%
APM
3
Avidity Partners Management
Texas
$5.23M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.07M +$88.2K +3,805 +2%
Citadel Advisors
5
Citadel Advisors
Florida
$3.95M -$277K -11,948 -7%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$3.71M -$12.4M -536,662 -77%
TCM
7
Tang Capital Management
California
$3.65M – – –
Federated Hermes
8
Federated Hermes
Pennsylvania
$3.51M +$1.72K +74 +0%
PM
9
Prosight Management
Texas
$3.04M +$1.85M +80,016 +157%
AG
10
Artal Group
Luxembourg
$2.32M – – –
PFMU
11
Privium Fund Management (UK)
United Kingdom
$2.03M +$157K +6,794 +8%
LCM
12
Laurion Capital Management
New York
$1.9M – – –
BlackRock
13
BlackRock
New York
$1.73M +$125K +5,375 +8%
BOTOTLSJU
14
Board of Trustees of The Leland Stanford Junior University
California
$1.52M -$807K -34,827 -35%
OMC
15
OUP Management Company
Pennsylvania
$1.35M – – –
Renaissance Technologies
16
Renaissance Technologies
New York
$1.09M -$636K -27,442 -37%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$847K -$37.1K -1,600 -4%
OMC
18
Oasis Management Company
Cayman Islands
$847K – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$805K +$75.1K +3,238 +10%
GCP
20
GSA Capital Partners
United Kingdom
$712K +$78.8K +3,399 +12%
Two Sigma Investments
21
Two Sigma Investments
New York
$692K -$172K -7,423 -20%
CAM
22
Cormorant Asset Management
Massachusetts
$662K – – –
Millennium Management
23
Millennium Management
New York
$443K -$720K -31,047 -62%
BCM
24
Bridgeway Capital Management
Texas
$433K +$56.3K +2,429 +15%
Man Group
25
Man Group
United Kingdom
$371K +$240K +10,367 +185%
1
2 3

LENZ Hedge Fund Activity: Q4 2022 in Review

66 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2022, worth a combined $95.4M — up 4.6% from $91.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LENZ positions and 9 closed out — a net gain of 4 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $13.7M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.

  • 66 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2022, up from 63 in Q3 2022.
  • Funds reported $95.4M of LENZ Therapeutics stock for Q4 2022, up 4.6% quarter-over-quarter.
  • 13 funds opened new LENZ Therapeutics positions in Q4 2022 and 9 closed out, a net change of +4 holders.
  • The largest LENZ Therapeutics buyer in Q4 2022 was EcoR1 Capital, an estimated $13.7M added.
  • The largest LENZ Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $12.4M sold.

Based on aggregated 13F filings for Q4 2022.